Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2028

Conditions
Alport Syndrome
Interventions
BIOLOGICAL

hUC-MSC

"This group of patients received a total of 2 peripheral intravenous Human umbilical cord mesenchymal stem cells (hUC-MSC) infusions during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days, and the single infusion dose was approximately 2×1000,000 cells/Kg.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."

DRUG

Placebo control drug

"This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."

All Listed Sponsors
lead

Guangzhou Women and Children's Medical Center

OTHER